A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.

Question

Six frontier AI models put this at 15% by 18 Sept 2029. Full reasoning from every model.

WillHappen.ai · Accepted Answer

15% — the median of 6 frontier models, resolving by 2029-09-18.

Answer

Gemini (Google): 8% — Clinical pipelines for HSV gene editing are barely in Phase 1/2, making a Phase 3 initiation by late 2029 historically unprecedented. Leading programs like BDgene (BD111) and Fred Hutch remain in early safety cohorts, requiring multi-year dose-escalation readouts. Transition from Phase 1 through Phase 2 typically demands 4 to 6 years in latent viral indications before clearing pivotal IND gates. A major safety scare or off-target delivery failure in sensory ganglia remains the primary risk that would stall clinical progression.

Answer

Claude (Anthropic): 8% — Success hinges on HSV gene-editing programs clearing Phase 1/2 with strong efficacy data before 2029, which is a tight timeline. Fred Hutch and similar HSV gene-editing programs are still preclinical or early Phase 1, far from Phase 3 readiness. Typical gene therapy/editing programs take 7-10+ years from preclinical to Phase 3, and HSV latency biology adds complexity to proving cure efficacy. A major funding or partnership breakthrough with a large pharma accelerating trials would be the main thing that could change this outlook.

Answer

GPT (OpenAI): 18% — The bottleneck is turning promising HSV gene-editing delivery into durable, regulator-acceptable human efficacy and safety data. A sponsor must complete IND-enabling work, then Phase 1/2 dosing and follow-up before a registered Phase 3 can begin by September 2029. Most in-vivo gene-editing programs do not reach Phase 3 within roughly three years of first-in-human work, especially for a latent viral reservoir. Odds rise sharply if Fred Hutch or another developer reports multi-patient viral suppression with no major immune or off-target signal by 2027.

Answer

Grok (xAI): 18% — Whether any HSV gene-editor already in/near Phase 2 by 2027 finishes that stage in time. No CRISPR or meganuclease HSV program had even entered Phase 1 by late 2023; first-in-human typically still 2025-27. Sponsors must clear IND, Ph1 safety and a Ph2 efficacy signal by ~2028 to start Ph3 before 2029. Novel gene editors historically take 5+ years from FIH to Ph3; only an unexpectedly rapid 2026 Ph2 readout would lift this above ~20%.

Answer

DeepSeek (DeepSeek): 12% — No HSV gene-editing candidate has cleared Phase 1/2 safety, and a Phase 3 start needs a sponsor, funding, and FDA sign-off inside three years. Fred Hutch's meganuclease work is still preclinical; no HSV gene-editing therapy has posted Phase 1 efficacy data as of late 2026. Gene-editing trials typically take 4-7 years from first-in-human to Phase 3, and HSV's latent reservoir makes endpoints hard to define. The one thing that would change this: a well-funded sponsor reporting positive Phase 2 HSV shedding data and an FDA agreement on a pivotal design before 2028.

Answer

Qwen (Alibaba): 18% — HSV gene-editing must clear Phase 1/2 safety and efficacy gates in ~2 years to file a Phase 3 protocol by mid-2029. Fred Hutch's meganuclease work (HSV-2) is still in early-stage preclinical/IND-enabling phases as of 2025; no IND has been filed for a gene-editing HSV therapy, so Phase… Phase 1/2 dose-escalation and safety readouts typically require 18-30 months before a Phase 3 protocol can be justified to regulators, leaving almost no buffer before… A surprise fast-track designation or an already-enrolled Phase 1/2 trial (e.g., from a company not yet public) that shows strong safety by late 2027 would be the main…

A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.

The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.

A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.

The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.

The US FDA approves an in vivo CRISPR gene editing therapy before January 1, 2028.